Public company intelligence preview
OMNICELL INC
53 insider trades surfaced from the last year. This page shows only aggregate signals, not the underlying transactions, people, filings, filters, or AI workspace.
Snapshot
A narrow read on a much deeper workspace.
The preview gives search visitors enough signal to understand coverage. It does not expose transaction records, person-level profiles, filters, comparisons, or analyst workflows.
Insider compensation
Public aggregate: $3.8M average total compensation across covered insiders.
Governance movement
Public aggregate: 3 governance events in the last year.
Institutional ownership
Public aggregate: 260 holders from the latest quarter.
Restricted sales and governance
Public counts, not the investigation layer.
The full product opens the underlying filings, insider context, historical holdings, comparison tools, and AI analysis.
Market context
Basic quote context for the preview.
Company note
Context before the data.
Company Overview
Omnicell Inc. is a Healthcare company in the Health Information Services industry that provides autonomous medication management solutions for hospitals, pharmacies, and other care settings. Its business spans automation hardware, robotics, IV compounding systems, and a cloud platform, with a strategic push toward the “Autonomous Pharmacy” model. Recent filings show the company relies heavily on the U.S. market, long implementation cycles, and a growing recurring-revenue base tied to services, SaaS, and its installed customer footprint.
Executive Compensation Practices
For a company like Omnicell, executive compensation is likely tied to a mix of revenue growth, recurring revenue expansion, ARR, gross margin, and cash flow performance, rather than just one-time product sales. The 2025 filings show management facing pressure from tariffs, higher employee-related costs, commissions, restructuring, and share-based compensation, so pay plans may emphasize operating discipline and margin improvement alongside growth. In Healthcare and especially Health Information Services, executives are often rewarded for multi-year implementation success, customer retention, compliance execution, and progress in subscription-style and software-driven revenue.
Insider Trading Considerations
Omnicell’s long sales and installation cycles, plus its mix of hardware, software, and recurring services, can make insider activity especially sensitive to backlog, ARR trends, and large customer conversion timing. Because the business is exposed to healthcare regulation, tariff risk, supply-chain constraints, and customer capital budgeting cycles, insiders may trade around periods when they have better visibility into order flow, implementation delays, or margin pressure. The company’s reliance on share-based compensation and its active use of buybacks and debt repayment can also influence trading patterns, as executives may buy or sell around vesting events, blackout windows, or material updates tied to recurring revenue and margin trends.
Unlock the full OMCL insider intelligence workspace.
Move from public aggregate counts into transaction-level detail, people, filings, compensation history, ownership shifts, export tools, and AI-assisted analysis.